Sign up
Pharma Capital

Optibiotix Health eyes up future projects

Per Rehne of Optibiotix Health (LON:OPTI) tells Proactive how the company's commercial journey through clinical trails, manufacturing and ultimately selling is a careful process of which he's been perfecting since he joined nine months ago. OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. Expanding the worldwide Optibiotix project portfolio is now the focus...hear how Per and the team intend to do just that.

 

View full OPTI profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.